Metabolic

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.

A first-in-class dual GIP and GLP-1 receptor agonist with superior weight loss and glycemic control versus GLP-1 mono-agonists.

An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials.

A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.

The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.

A once-weekly GLP-1 receptor agonist for type 2 diabetes with demonstrated cardiovascular risk reduction.

An investigational once-weekly amylin agonist studied with semaglutide (CagriSema) for powerful combined weight loss.

A modified fragment of growth hormone developed for obesity that promotes fat metabolism in animals but failed to beat placebo in human weight-loss trials.

The lipolytic C-terminal fragment of growth hormone studied in animals for fat loss without growth-hormone-like effects on glucose or IGF-1.

An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.

An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and type 2 diabetes, with advanced trials in China.

An FDA-approved synthetic amylin analogue used with insulin to improve post-meal glucose control and reduce appetite.

An experimental peptide that targets the blood supply of white fat, causing dramatic weight loss in primates but with significant kidney toxicity.

An investigational once-daily oral GLP-1 receptor agonist that is a small molecule rather than a peptide, studied for obesity and diabetes.

An FDA-approved once-daily GLP-1 receptor agonist for type 2 diabetes, also studied for effects beyond glucose control.

An FDA-approved GLP-2 analogue that promotes intestinal growth in short bowel syndrome, reducing dependence on IV nutrition.

The natural gut hormone behind the entire GLP-1 drug class, released after eating to boost insulin and reduce appetite.

A natural gut hormone that promotes growth and repair of the intestinal lining, the basis for the drug teduglutide.

An investigational long-acting GLP-1 agonist that showed cardiovascular and kidney benefits in a large outcomes trial.

The hormone that raises blood sugar, FDA-approved as an emergency treatment for severe hypoglycemia and a target of the newest dual and triple agonists.

An investigational non-peptide weight-loss drug that suppresses appetite by acting on brain neurotransmitters.

An experimental small-molecule enzyme inhibitor studied in animals for fat metabolism and muscle, popular on longevity resources.

An essential vitamin given by injection for deficiency and widely offered in wellness clinics for energy, though benefit without deficiency is limited.

A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval.

Amgen's monthly-dosed obesity drug that pairs GLP-1 activation with GIP receptor blockade, reaching around 20% weight loss in Phase 2.

Viking Therapeutics' dual GLP-1 and GIP agonist in Phase 3 as an injection, with an oral version showing rapid early weight loss.

Novo Nordisk's single-molecule GLP-1 and amylin agonist, in oral and injectable forms, that showed strong early weight loss and is heading to Phase 3.

A once-weekly amylin analogue from Zealand and Roche being developed as a potentially better-tolerated obesity treatment, with positive Phase 2 results.

Altimmune's GLP-1 and glucagon dual agonist being developed for obesity and metabolic liver disease, with a focus on preserving lean mass.

A long-acting GLP-1 agonist in Phase 3 development, notable for the potential of extended, less frequent dosing.

Pfizer's oral small-molecule GLP-1 agonist whose development was discontinued after tolerability and safety signals.

A muscle-preserving antibody that blocks activin receptors to reduce fat while increasing lean mass, being studied alongside GLP-1 drugs.

A triple GLP-1, GIP, and glucagon agonist developed mainly for metabolic liver disease.

Lilly's selective amylin agonist that reached about 20% weight loss in Phase 2 with milder gut side effects than GLP-1 drugs, now in Phase 3 alone and as an add-on to tirzepatide.

An ultra-long-acting GLP-1 agonist with a roughly 15-day half-life built for once-monthly injection, the centerpiece of Pfizer's Metsera acquisition and now heading into ten Phase 3 trials.

Structure Therapeutics' once-daily oral small-molecule GLP-1 agonist that produced 16.3% placebo-adjusted weight loss at 44 weeks, the highest reported for any GLP-1 pill so far.

A once-weekly GLP-1/GIP dual agonist in the tirzepatide class that delivered 19.2% weight loss at 48 weeks in a Chinese Phase 3 trial and is now in global pivotal studies at higher doses.

Roche's signaling-biased GLP-1/GIP dual agonist that produced 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2, the strongest number in its class, with Phase 3 starting in 2026.

AstraZeneca's once-daily oral GLP-1 pill, 10.5% weight loss at 26 weeks in Phase 2b, now entering a broad Phase 3 program.

Novo Nordisk's licensed triple agonist that produced up to 19.7% weight loss in 24 weeks in a Chinese Phase 2, the company's answer to retatrutide.

Hengrui's once-daily oral GLP-1 pill with two positive Chinese Phase 3 trials (about 11% weight loss at 50 weeks), filed in China and in global Phase 2 through Kailera.

AstraZeneca's weekly amylin analog that jumped to Phase 3 in 2026 as a monotherapy and as an add-on to GLP-1 drugs, with detailed Phase 2 numbers still unpublished.

Pfizer's monthly amylin analog (from Metsera) with a 19-day half-life, being co-formulated with berobenatide into a once-monthly GLP-1 plus amylin combination.

An antibody that blocks the cannabinoid CB1 receptor outside the brain; alone it did little, but with semaglutide it reached 22.3% weight loss at 52 weeks and halved regain during a drug holiday.

Novo Nordisk's oral peripherally acting CB1 blocker: 7.1 kg weight loss in 16 weeks in Phase 2a, but with dose-related anxiety, irritability and sleep problems that Phase 2b must resolve.

Boehringer Ingelheim's first-in-class triple agonist that swaps glucagon for the NPY2 (PYY-type) satiety receptor, entering Phase 2 in July 2026 with no efficacy data yet.

A weekly FGF21 analog that reversed cirrhosis in a subset of MASH patients at 96 weeks in Phase 2b, with three Phase 3 SYNCHRONY trials under way.

A glycoPEGylated FGF21 analog dosed weekly or every two weeks, now owned by Roche and in two Phase 3 MASH trials.

GSK's once-monthly FGF21 analog, acquired for $1.2 billion upfront, with FDA Breakthrough Therapy designation for MASH and Phase 2 results published in 2026.

An oral pan-PPAR agonist for MASH whose 1,000-patient Phase 3 (NATiV3) completed its last patient visit in September 2026, with results due by year end.

A 12 amino acid peptide discovered by AI-guided prohormone screening at Stanford that cut food intake by up to half in mice and minipigs through a non-GLP-1 pathway; no human trial exists.

An oral AMPK activator with one 28-day human pilot in type 2 diabetes and recent mouse data, now sold as a research chemical and promoted as an exercise mimetic or metformin replacement.

A mitochondrial uncoupler that reversed obesity and insulin resistance in mice with a wider safety margin than DNP, now sold as a supplement-style research chemical with no human data.

A PPAR-delta agonist that GSK abandoned in 2007 after long-term rodent studies produced cancers in multiple organs; still sold widely for endurance and fat loss despite the signal and a WADA ban.

A REV-ERB agonist marketed as an exercise mimetic; animal data only, very poor oral bioavailability, and published work questioning whether its effects even run through REV-ERB.

A Khavinson tetrapeptide sold as a pancreatic bioregulator riding the metabolic-health wave; preclinical, single-group evidence only.